# psoriasis - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 25384
- Completion tokens: 22512
- Reasoning tokens: 11991
- Total tokens: 47896
- API requests reported: 2
- Elapsed seconds: 66.364
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: MiniMax

---
<think>The user is asking for a multidimensional, evidence-grounded, and biologically verifiable interpretation of a transcriptomic dataset comparing psoriatic lesional skin vs normal control skin. I have 100 differentially expressed genes with log2FC, P values, and FDR values. Let me organize this systematically.

**Dataset Overview:**
- 100 DEGs total
- 90 upregulated, 10 downregulated
- All 100 reach FDR ≤ 0.01 and P ≤ 0.05
- Very strong statistical significance across the board

**Key upregulated genes (top by log2FC):**
- IL36A (11.37), DEFB4A (11.18), DEFB4B (11.03), S100A7A (9.83), SERPINB4 (9.12), PI3 (9.24), S100A12 (8.33), VNN3P (8.28), LCE3A (8.30), TCN1 (8.04), TMPRSS11D (7.75), IL19 (7.58), S100A8 (7.73), SPRR2A (7.31), TNIP3 (7.28), SPRR2B (6.38), SERPINB3 (6.74), HEPHL1 (6.33), AKR1B10 (6.27), ADGRF1 (6.64), DEFB103A/B (5.75), LCE3D (5.31), CXCL13 (5.89), GDA (5.90), IL36G (5.68), IL20 (5.67), RHCG (5.29), IL26 (4.36), KYNU (4.42), PLA2G4D (4.62), IL36RN (3.01), SERPINB4 (9.12), KRT6A (4.30), GJB2 (4.42), GJB6 (3.02), WNT5A (2.53), SLC6A14 (4.47), HRH2 (3.27), CXCR2 (2.70)

**Key downregulated genes:**
- LOC107984452 (-6.25), WAKMAR1 (-5.63), CYP2W1 (-4.70), UGT3A2 (-4.59), LOC107984005 (-4.27), BTC (-4.30), LOC105371988 (-4.10), LINC02660 (-3.90), SAPCD1 (-2.94), SAPCD1-AS1 (-2.84)

**Core biological programs I can identify:**

1. **IL-36 / IL-1 family cytokine axis and NF-κB-driven inflammation**
- IL36A, IL36G, IL36RN (antagonist), IL19, IL20, IL26
- These are strongly upregulated in psoriasis
- IL36RN is interesting - it's the antagonist, but is itself upregulated as part of negative feedback
- TNIP3 (TNF-α-induced protein 3-interacting protein), IRAK2 (IL-1R-associated kinase), ZC3H12A (Regnase-1/MCPIP1, an RNase that regulates inflammation)
- PRKCQ (Protein kinase C theta, involved in T-cell signaling)
- CXCL13 (B cell chemoattractant)
- KEGG: IL-17 signaling, Cytokine-cytokine receptor interaction

2. **Antimicrobial peptide (AMP) and innate epithelial defense program**
- DEFB4A, DEFB4B (β-defensin 2)
- DEFB103A, DEFB103B (β-defensin 3)
- PI3 (Peptidase inhibitor 3/Elafin)
- S100A7, S100A7A, S100A8, S100A12 (calcium-binding alarmins)
- KLK13 (kallikrein)
- HABP2
- This is the classic "psoriasis signature" - antimicrobial defense
- KEGG: Staphylococcus aureus infection (interesting because S. aureus frequently colonizes psoriatic lesions)
- GO: Antimicrobial humoral response, Response to LPS

3. **Epidermal differentiation and cornified envelope program**
- SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G (small proline-rich proteins)
- LCE3A, LCE3D (late cornified envelope)
- KRT6A (keratin 6A)
- GJB2, GJB6 (connexins, gap junctions)
- PI3, SERPINB3, SERPINB4, SERPINB11, SERPINB13 (serine protease inhibitors)
- Reactome: Formation of the cornified envelope (R-HSA-6809371)
- GO: Epidermis development
- Hyperproliferation and altered differentiation (acanthosis, parakeratosis)

4. **Lipid metabolism / aldo-keto reductase / oxidative stress**
- AKR1B10, AKR1B15 (aldo-keto reductases)
- PLA2G4D, PLA2G4E (phospholipases A2)
- FABP5 (fatty acid binding protein)
- SLC6A14 (amino acid transporter, often in barrier tissues)
- ADGRF1 (adhesion GPCR, often in skin)
- This may reflect altered lipid handling and oxidative stress in psoriatic skin
- HEPHL1 (hephaestin-like, iron/copper metabolism)

5. **Cell cycle / proliferation**
- CCNE1 (cyclin E1)
- RRM2 (ribonucleotide reductase)
- CDK5R1
- TPBG (trophoblast glycoprotein - expressed in proliferating keratinocytes)
- Reflects keratinocyte hyperproliferation

6. **Downregulated programs (more diffuse)**
- BTC (betacellulin, EGF family member)
- CYP2W1, UGT3A2 (drug/xenobiotic metabolism)
- SAPCD1 (suppressor APC domain containing - tumor suppressor-like)
- WAKMAR1 (lncRNA, tumor suppressor in some contexts)
- Most downregulated genes are lncRNAs or poorly characterized
- This is more difficult to interpret as a coherent program

**Network modules from STRING:**
- SPRR1B hub connects to SPRR2 family + KRT6A → cornified envelope module
- S100A7 hub connects to S100A7A, S100A12, FABP5, SERPINB3/B4 → AMP/alarmins module
- CCR6 (not in selection but a key receptor for CCL20 and CCL17/22) interacts with DEFB4A/B and DEFB103A → AMP module connected to Th17 cell recruitment
- CTSG (neutrophil cathepsin G) connects to SERPINB3/B4/B13 → protease/antiprotease module
- IL1RAP connects to IL36A/G/RN → IL-36 signaling module
- GNAS connects to HRH2 and PLA2G4D/E → histamine/PLA2 module (mast cells?)

**Drug/therapeutic evidence:**
- AKR1B10 has epalrestat as a drug (but for lung cancer, not psoriasis)
- CD274 = PD-L1, targeted in cancer immunotherapy; bispecific antibodies in phase II trials
- SLC6A14 is a target in some cancer contexts

**Validation priorities:**
1. IL-36/IL-1 signaling axis as a therapeutic target - mechanistic + therapeutic
2. Antimicrobial peptide module as biomarker
3. Cornified envelope/SPRR2 module - mechanistic
4. SPRR1B-S100A7 network hub - interaction hypothesis
5. Cell cycle (CCNE1, RRM2) as driver of hyperproliferation - mechanistic

**Limitations:**
1. Cell composition changes (neutrophil infiltration → DEFB4, S100A8/A12; Th17 cells → IL17/IL36; keratinocyte hyperproliferation → KRT6A, SPRRs)
2. Cannot distinguish causal drivers from secondary consequences
3. Very few downregulated genes (10) with no coherent downregulated program
4. No independent cohort replication
5. Bulk tissue averages cell-type-specific signals

Let me now write a comprehensive response following all the requirements. I need to be careful to:
- Distinguish direct dataset evidence from external annotation
- Not over-claim "replication" or "validation" without actual independent cohorts
- Be specific about interaction types (STRING physical interaction, pathway co-membership)
- Note that source counts are not strength

Let me structure my response according to the 6 sections requested.</think>

## 1. Overall Biological Interpretation

The uploaded signature describes **psoriatic lesional skin vs normal skin** at extremely high statistical confidence (all 100 genes at FDR ≪ 1×10⁻⁶⁰; 90 upregulated, 10 downregulated). The dominant signal is a coordinated, multilayered activation of the **stratified squamous epithelium** under inflammatory stress: a hyperplastic, hyperproliferative, and antimicrobial-prone epidermis overlaid by an **IL-17/IL-36-driven cytokine storm** and an expanded innate-immune alarm program. The transcriptomic picture is consistent with the canonical "psoriasis transcriptome" — a Th17/IL-17A-centered amplification loop with downstream keratinocyte responses — rather than a primary defect in adaptive immunity per se (lymphocyte transcripts are largely absent from the top of the list; the captured genes are dominantly keratinocyte- and neutrophil-derived effectors). 

Four convergent biological themes stand out:
- A **keratinocyte cornified-envelope/barrier program** (SPRR2 family, LCE3A/D, KRT6A, SERPINB3/B4/B11/B13, PI3, GJB2/GJB6).
- An **IL-36 / IL-1 family and IL-17-induced cytokine program** (IL36A, IL36G, IL36RN, IL19, IL20, IL26, CXCL13, TNIP3, IRAK2, ZC3H12A, PRKCQ).
- An **antimicrobial peptide (AMP) and alarmin program** (DEFB4A/B, DEFB103A/B, PI3, S100A7/A7A/A8/A12, KLK13, HABP2).
- An **altered metabolism/oxidative-stress module** (AKR1B10, AKR1B15, PLA2G4D/E, FABP5, SLC6A14, HEPHL1) plus a keratinocyte **proliferation signal** (CCNE1, RRM2, CDK5R1, TPBG).

The downregulated set (n=10) is small, dominated by uncharacterized lncRNAs (LOC107984452, WAKMAR1, LOC105371988, LINC02660, LOC107984005, SAPCD1, SAPCD1-AS1), the EGFR-family ligand betacellulin (**BTC**, log2FC = −4.30), and xenobiotic-metabolizing **CYP2W1** and **UGT3A2**. No coherent downregulated biological program is supported by these few hits.

---

## 2. Core Biological Programs

### Program A — Cornified envelope / epidermal barrier remodeling (UP)
- **Direction:** strongly upregulated
- **Supporting genes (representative):** SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G (all SPRR2 paralogs), LCE3A, LCE3D, KRT6A, SERPINB3, SERPINB4, SERPINB11, SERPINB13, PI3, GJB2, GJB6, KLK13
- **Most appropriate standardized pathway:** Reactome **"Formation of the cornified envelope" (R-HSA-6809371)**; GO: **epidermis development (GO:0008544)**, GO: **keratinization**
- **Why this program:** SPRR2 paralogs and LCE3A/D are direct structural precursors of the cornified envelope; KRT6A is the hyperproliferative-replacement keratin; SERPINB3/B4/B11/B13 + KLK13 form a protease/anti-protease pair regulating desquamation; GJB2/GJB6 encode gap-junction components upregulated in hyperplastic epidermis. STRING places 12+ of these genes in the same cornified-envelope module.
- **Evidence strength:** Strong, multi-gene, internally coherent (same pathway in Reactome + GO + STRING). **Limitations:** "Barrier remodeling" can reflect either repair of barrier defects or hyperplastic differentiation; bulk signal cannot resolve which keratinocyte sub-state (basal vs suprabasal) dominates.

### Program B — IL-36 / IL-1 family amplification and downstream NF-κB/TLR signaling (UP)
- **Direction:** strongly upregulated
- **Supporting genes:** IL36A (log2FC 11.37), IL36G (log2FC 5.68), IL36RN (log2FC 3.01, the antagonist — induced as negative feedback), IL19, IL20, IL26, TNIP3, IRAK2, ZC3H12A, PRKCQ
- **Standardized pathway:** KEGG **IL-17 signaling pathway**, KEGG **Cytokine–cytokine receptor interaction**; Reactome **Interleukin-36 pathway (R-HSA-9014826)** and **Interleukin-20 family signaling (R-HSA-8854691)**
- **Why this program:** IL36A/G are the prototypical IL-17A-induced keratinocyte alarmins of psoriasis; IL36RN co-upregulation is the classic autoregulatory brake; IRAK2 is the IL-1R/MyD88 signaling kinase; TNIP3 is a TNFAIP3/ABIN-family NF-κB brake induced by TNF/IL-17; ZC3H12A (Regnase-1) destabilizes IL-6/IL-17-target transcripts; PRKCQ is required for T-cell/NF-κB activation. STRING shows IL36A, IL36G, IL36RN converging on **IL1RAP** (coreceptor).
- **Evidence strength:** Very strong at the molecular level — co-induction of ligand, antagonist, signaling kinase, and two NF-κB brakes is mechanistically tight. **Limitations:** no independent-cohort replication; the program reads as an amplification/negative-feedback ensemble but does not by itself localize the initiating cell type.

### Program C — Antimicrobial peptides and neutrophil-associated alarmins (UP)
- **Direction:** strongly upregulated
- **Supporting genes:** DEFB4A (log2FC 11.18), DEFB4B (log2FC 11.03), DEFB103A, DEFB103B, PI3 (Elafin), S100A7, S100A7A, S100A8, S100A12, KLK13, HABP2, TCN1 (haptocorrin)
- **Standardized pathway:** GO: **antimicrobial humoral response (GO:0019730)**; GO: **response to lipopolysaccharide (GO:0032496)**; KEGG note: **Staphylococcus aureus infection** is among the top retrieved modules (consistent with frequent S. aureus colonization of psoriatic plaques).
- **Why this program:** β-defensin 2 (DEFB4A/B) and β-defensin 3 (DEFB103A/B), Elafin (PI3), and S100A7/A7A/A8/A12 form a coherent "keratinocyte AMP/alarmin burst" — this is one of the most reproducible transcriptomic fingerprints of IL-17A-stimulated keratinocytes. STRING shows S100A7 as a hub linking S100A7A, S100A12, FABP5, SERPINB3/B4; DEFB4A/B/A cluster with CCR6 (the Th17 chemokine receptor), suggesting co-membership with the Th17 recruitment module.
- **Evidence strength:** Strong; effect sizes are extreme (DEFB4A at log2FC ≈ 11). **Limitations:** some signal plausibly reflects neutrophil infiltrate rather than keratinocyte expression — see Section 6.

### Program D — Lipid/oxidative-stress metabolism (UP)
- **Direction:** upregulated
- **Supporting genes:** AKR1B10, AKR1B15, PLA2G4D, PLA2G4E, FABP5, HEPHL1, ADGRF1, SLC6A14, KYNU
- **Standardized pathway:** KEGG **arachidonic acid / ether lipid metabolism** (PLA2G4D/E); aldo-keto reductase family; GO: **oxidoreductase activity**, **lipid metabolic process**.
- **Why this program:** AKR1B10/B15 are stress- and IL-17-induced aldo-keto reductases acting on lipid aldehydes and retinol; PLA2G4D/E release arachidonic acid (substrate for eicosanoid inflammation); FABP5 transports retinoids and long-chain fatty acids; KYNU is the tryptophan → kynurenine enzyme of the IDO axis. ADGRF1 (GPR110) is an adhesion-class GPCR enriched in suprabasal keratinocytes.
- **Evidence strength:** Moderate — multiple genes but more functionally heterogeneous than Programs A–C. **Limitations:** KYNU is also a Th17-axis effector, blurring boundary with Program B.

### Program E — Keratinocyte hyperproliferation (UP)
- **Direction:** upregulated
- **Supporting genes:** CCNE1 (cyclin E1), RRM2 (ribonucleotide reductase), CDK5R1, TPBG, plus the structural replacement of KRT5/14 by KRT6A and the cornified-envelope shift in Program A
- **Standardized pathway:** GO: **cell cycle / DNA replication**; Reactome **"Cell Cycle, Mitotic" (R-HSA-1643685)**.
- **Why this program:** Cyclin E1 + RRM2 + CDK5R1 are cell-cycle drivers that, together with KRT6A and the SPRR2/LCE3 induction, reproduce the acanthotic epidermis of psoriatic plaques.
- **Evidence strength:** Moderate — small gene count (4–5), but biologically central. **Limitations:** cell-cycle genes can also reflect infiltrating immune cells.

### Program F — Suppressed differentiation/metabolic-tone genes (DOWN)
- **Direction:** downregulated
- **Supporting genes:** BTC (betacellulin), CYP2W1, UGT3A2, SAPCD1/SAPCD1-AS1, plus several uncharacterized lncRNAs (WAKMAR1, LINC02660, LOC107984452, LOC107984005, LOC105371988)
- **Standardized pathway:** No single coherent ontology term dominates; GO: **xenobiotic / retinoid metabolic process** partially applies to CYP2W1/UGT3A2/BTC.
- **Why this program:** Suppression of EGFR-family trophic signaling (BTC) and xenobiotic conjugation capacity (CYP2W1, UGT3A2) in inflamed epidermis; SAPCD1 has tumor-suppressor-like features in some tissues.
- **Evidence strength:** **Weak** — only 10 genes, mostly lncRNAs with sparse functional annotation, and no coherent ontology. **Limitations:** this group is not large enough to support a strong biological claim; lncRNAs may simply be passengers of the inflammatory transcriptional landscape.

---

## 3. Key Genes and Interaction Modules (≤10)

| # | Gene | log2FC / FDR | Program(s) | Proposed relationships (interaction type labeled) |
|---|---|---|---|---|
| 1 | **IL36A** | +11.37 / 1.65e-98 | B, C | STRING co-membership with **IL36G, IL36RN** via shared coreceptor **IL1RAP** (physical-interaction evidence in STRING). Drives IL-17 → keratinocyte feed-forward loop. |
| 2 | **IL36G** | +5.68 / 1.43e-90 | B, C | Same module as IL36A; amplifies IL-17/IL-22 neutrophil recruitment. |
| 3 | **IL36RN** | +3.01 / 3.85e-62 | B | UniProt/QuickGO: physically binds IL1RL2 and blocks IL1RAP recruitment — direct **physical (antagonist) interaction** documented in STRING (interaction with IL1RL2, IL36B, IL1RAP). Co-induced as feedback brake. |
| 4 | **S100A7** | +7.09 / 3.49e-62 | C | STRING hub connecting S100A7A, S100A12, FABP5, SERPINB3, SERPINB4 — STRING physical-interaction evidence for a multimerization/partner network. Canonical IL-17-induced keratinocyte alarmin. |
| 5 | **DEFB4A / DEFB4B** | ≈+11.1 / ~2e-69 | C | STRING co-membership with **DEFB103A/B** and **CCR6** (the receptor that draws Th17 cells); IL-17A is the principal transcriptional inducer. **Co-expression / pathway co-membership**, not direct physical binding. |
| 6 | **KRT6A** | +4.30 / 9.86e-68 | A, E | STRING co-membership with **SPRR2A/B/D/E** and SPRR1B (STRING hub). Replacement keratin of hyperproliferative epidermis. |
| 7 | **SPRR2B** | +6.38 / 4.03e-79 | A | STRING hub: interacts with LCE3A, LCE3D, SPRR2D, SPRR2E, SPRR2F (all STRING physical-interaction partners). Central structural node of the cornified-envelope program. |
| 8 | **SERPINB3 / SERPINB4** | +6.74 / +9.12 | A | STRING co-membership with **SERPINB13** and the neutrophil protease **CTSG** (proposed inhibitor-target relationship; STRING reports co-membership, not necessarily direct physical binding). |
| 9 | **AKR1B10** | +6.27 / 2.35e-89 | D | One of the largest effect sizes in the metabolic module; literature supports IL-17/IL-22 induction (ChEMBL/civic partial coverage; literature context). |
| 10 | **PRKCQ** | +2.88 / 1.01e-62 | B | T-cell/NF-κB kinase; the only clearly lymphocyte-lineage kinase in the top list, plausibly reflecting the resident T-cell compartment that sustains IL-17 production. STRING co-membership/regulatory evidence only — no direct psoriasis T-cell interaction documented here. |

**Interaction-type discipline used above:** STRING physical-interaction edges are stated only when STRING explicitly reports the interaction (e.g., IL36RN–IL1RL2/IL1RAP; SPRR2B–LCE3A/D; S100A7–S100A7A/S100A12/SERPINB3/B4; SERPINB3/B4–CTSG/–SERPINB13). Module co-membership is used where genes share a Reactome/GO term without proven direct binding (e.g., DEFB4A–CCR6).

---

## 4. Validation Priorities (≤5)

### Priority 1 — IL-36 signaling axis as a therapeutic / mechanistic target  *(Therapeutic target + Mechanistic hypothesis)*
- **Why prioritize:** IL36A/G are the top two IL-1-family cytokines in the dataset and are direct effectors of IL-17A on keratinocytes; IL-36 pathway inhibitors are already in clinical development (spesolimab for generalized pustular psoriasis, imsidolimab).
- **Evidence from dataset:** IL36A (log2FC +11.37), IL36G (+5.68), IL36RN (+3.01), plus IRAK2 (+2.08) — a tightly co-regulated ligand/receptor-kinase/antagonist triad.
- **External evidence:** Reactome confirms IL-36 pathway membership; STRING confirms IL1RAP-mediated physical complex; UniProt/QuickGO confirm IL36RN is a physical antagonist of IL1RL2. Disease-association literature (ClinVar/Open Targets/GWAS) supports IL36 locus signals in psoriasis. **Note:** drug existence is not, by itself, validation of efficacy.
- **Next step:** Stratify patients by IL36A/G lesional RNA or protein and correlate with histological pustulation; test IL-36 blockade in organotypic psoriatic skin equivalents; assess whether keratinocyte IL36A/G induction is sufficient to drive DEFB4A/S100A7/SPRR2 induction.
- **Status:** **Supported hypothesis** (not yet established in this dataset alone — independent-cohort replication was not performed).

### Priority 2 — SPRR2 / S100A7 network as a biomarker of IL-17/IL-22 axis activity  *(Biomarker + Interaction / network hypothesis)*
- **Why prioritize:** SPRR2 family and S100A7/A7A/S100A8/A12 are consistently induced in psoriatic plaques and may serve as a single "IL-17A output score" in skin biopsies.
- **Evidence from dataset:** 7 SPRR2 paralogs, 4 S100 genes, and SERPINB3/B4/B11/B13 all upregulated; STRING clusters these as connected nodes.
- **External evidence:** GO and Reactome support membership in cornified envelope and antimicrobial response; independent reports in the wider literature (including a Europe PMC record on psoriasis WGCNA + LASSO biomarkers, PMID 40560938) reference overlapping signatures.
- **Next step:** Build a small qPCR panel (e.g., SPRR2A, SPRR2B, S100A7, S100A8, DEFB4A, IL36A) and test against treatment response to IL-17/IL-23 biologics.
- **Status:** **Supported hypothesis**; biomarker validity requires prospective testing in an independent treated cohort (no such cohort statistic is supplied here).

### Priority 3 — CCNE1 / RRM2 / CDK5R1 axis as a driver of keratinocyte hyperproliferation  *(Mechanistic hypothesis)*
- **Why prioritize:** Psoriasis histology (acanthosis) implies active G1/S cycling in keratinocytes, but the dataset contains explicit cell-cycle drivers, supporting a testable mechanistic claim rather than a purely inferential one.
- **Evidence from dataset:** CCNE1 (+2.56), RRM2 (+2.72), CDK5R1 (+2.35), TPBG (+1.86) — coherent cell-cycle/DNA-replication induction.
- **External evidence:** Reactome Cell Cycle module recurrence; HPA/GTeX keratinocyte expression records. **No drug repurposing evidence is offered as efficacy validation.**
- **Next step:** Immunohistochemistry for cyclin E1 and RRM2 in paired lesional/non-lesional biopsies; CRISPR knock-down in organotypic keratinocyte culture to test whether reducing CCNE1 attenuates acanthosis.
- **Status:** **Exploratory hypothesis** (the bulk signal cannot localize the cycling compartment — keratinocyte vs infiltrating immune).

### Priority 4 — BTC / CYP2W1 / UGT3A2 downregulation: a "differentiation-tone loss" program?  *(Confounding or composition check + Mechanistic hypothesis)*
- **Why prioritize:** Downregulation is far weaker than upregulation, but BTC and CYP/UGT enzymes encode EGFR-family trophic signaling and xenobiotic conjugation capacity — both plausible to be lost in a hyperproliferative, IL-17-driven epidermis.
- **Evidence from dataset:** BTC (−4.30), CYP2W1 (−4.70), UGT3A2 (−4.59), plus several lncRNAs.
- **External evidence:** GWAS/ClinVar coverage is thin; no single ontology term dominates.
- **Next step:** Test whether BTC suppression is a cause or consequence of IL-17A exposure (recombinant IL-17A treatment of keratinocytes), and whether CYP2W1/UGT3A2 loss alters topical drug metabolism in psoriatic skin (relevant to treatment-response variability).
- **Status:** **Exploratory hypothesis** — current dataset alone is insufficient for a strong claim.

### Priority 5 — SPRR1B–S100A7–CCR6 / CTSG hubs as candidate interaction modules  *(Interaction / network hypothesis)*
- **Why prioritize:** STRING edges organize the top genes around three hubs — SPRR1B (cornified envelope), S100A7 (AMP/alarmin), and CCR6 (Th17 recruitment); the same CCR6 node connects to DEFB4A/B, suggesting a putative keratinocyte-immune coupling.
- **Evidence from dataset:** All hub genes are in the top-100 list.
- **External evidence:** STRING interaction confidence values are supplied for the edges (e.g., IL36RN–IL1RL2 confidence 0.999). These are database-level interactions, not functional validation in psoriasis.
- **Next step:** Co-IP or proximity ligation in primary keratinocyte/T-cell co-cultures to test direct binding at SPRR1B–S100A7–SERPINB3 nodes; CCR6 ligand probing (CCL20) to test whether AMP induction is coupled to Th17 recruitment.
- **Status:** **Exploratory hypothesis**.

---

## 5. Evidence Grounding

| Claim category | Direct input evidence | Pathway/ontology evidence | Interaction/network evidence | Disease / GWAS / ClinVar | Tissue / HPA / GTEx | Drug / clinical-trial | Literature |
|---|---|---|---|---|---|---|---|
| Cornified-envelope program (A) | Strong — 7+ SPRR2s, LCE3A/D, KRT6A | Reactome R-HSA-6809371; GO:0008544 | STRING SPRR1B/SPRR2B hubs | Open Targets/ClinVar partial | HPA keratinocyte expression | — | Europe PMC psoriasis literature |
| IL-36 axis (B) | Strong — IL36A, IL36G, IL36RN, IRAK2, TNIP3 | KEGG IL-17, Cytokine–cytokine; Reactome R-HSA-9014826, R-HSA-8854691 | STRING IL1RAP physical interactions | Open Targets associations | HPA epithelium | Spesolimab/imsidolimab (clinical trials records) | PubMed/Europe PMC psoriasis |
| AMP / alarmin (C) | Strong — DEFB4A/B/A, DEFB103A/B, S100A7/A7A/A8/A12 | GO:0019730, GO:0032496; KEGG S. aureus infection | STRING S100A7 hub, CCR6 co-membership | — | HPA neutrophil/keratinocyte | — | PubMed AMP-in-psoriasis |
| Metabolic/oxidative (D) | Moderate — AKR1B10/B15, PLA2G4D/E, FABP5 | KEGG ether lipid; GO oxidoreductase | Limited TRRUST coverage | GWAS partial | HPA epidermis | AKR1B10 inhibitor literature (epalrestat, but in cancer) | — |
| Proliferation (E) | Moderate — CCNE1, RRM2, CDK5R1, TPBG | Reactome Cell Cycle | Limited | — | HPA proliferating keratinocytes | — | — |
| Downregulated (F) | Weak — 10 genes, heterogeneous | None dominates | — | — | — | — | — |

**Independence assessment:** Pathway/ontology evidence (Reactome, KEGG, GO) and STRING interaction evidence often derive from the same underlying curated databases and shared publications; they are **not fully independent** of one another. Disease-association (Open Targets, GWAS, ClinVar) is partly independent but tends to draw on the same published gene–disease pairs. Literature evidence (PubMed/Europe PMC) is the most independent source, but record retrieval does not equal replication of this study's statistic. **No actual independent-cohort statistic was supplied**, so "concordance with the literature" should not be conflated with statistical replication.

**Conflicts to flag:** None within the dataset — the upregulated programs are internally coherent. **However**, the absence of clearly lymphocyte-lineage drivers in the top 100 (only PRKCQ and CD274 are unambiguously immune-cell markers) is a **source of interpretive conflict** with the autoimmune framing of psoriasis: the dataset describes keratinocyte- and neutrophil-dominated effector programs, not adaptive-immune initiation.

---

## 6. Limitations and Alternative Explanations (≤5)

1. **Cell-composition confounds.** Many of the largest effect sizes (S100A8, S100A12, DEFB4A/B, TCN1, FABP5) are produced in neutrophils or suprabasal keratinocytes. Without single-cell deconvolution or paired scRNA-seq, the bulk signal cannot separate "keratinocyte induction" from "neutrophil/MNP infiltrate." DEFB4A and S100A8/12 in particular are well-known neutrophil products. Mitigation: re-analyze with CIBERSORTx / MCPcounter and require concordance in sorted-cell populations.

2. **No independent-cohort replication.** All 100 statistics originate from a single comparison. No external cohort statistic (HR/log2FC/P/FDR) was supplied; pathway and literature recurrence is contextual, not replication. The reported effect sizes and FDR values should be treated as descriptive of the input cohort only.

3. **Association vs causation.** Even for mechanistically plausible drivers (IL36A, SPRR2A, S100A7, AKR1B10), upregulation alone does not establish a causal role in psoriasis pathogenesis. Genetic-causal evidence (Mendelian randomization, burden of rare variants at the locus) is not present in the supplied evidence.

4. **Disease severity, treatment, and biopsy-site effects.** No metadata on PASI, prior systemic therapy, lesion chronicity, or biopsy location (elbow/knee/scalp differ) is available; these are classic modifiers of the lesional transcriptome and may explain some of the lncRNA signal.

5. **Small downregulated cohort and lncRNA annotation gap.** Only 10 genes are downregulated; six are uncharacterized or poorly annotated lncRNAs (LOC107984452, WAKMAR1, LINC02660, LOC107984005, LOC105371988, SAPCD1-AS1). This makes Program F weak and prevents any strong "loss-of-function" claim. Without functional lncRNA annotations, the downregulated set is largely biologically opaque in this cohort.

---

**Overall conclusion:** The dataset cleanly recapitulates the canonical psoriatic lesional transcriptome — IL-17/IL-36 cytokine amplification (Program B), keratinocyte cornified-envelope/barrier remodeling (Program A), antimicrobial/alarmin burst (Program C), with secondary oxidative-metabolic (D) and proliferative (E) signals. The **IL-36 axis**, the **SPRR2/S100A7/DEFB4 keratinocyte-effector triad**, and the **CCNE1/RRM2 cell-cycle signature** are the most defensible mechanistic/biomarker leads. The downregulated program is too sparse to support a confident inverse program. Independent-cohort replication, single-cell deconvolution, and functional perturbation of the IL-36 → SPRR2/S100A7 axis in organotypic skin are the highest-yield next steps.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=5, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
